1. Expression and downregulation of cytotoxic cell protease 1 or Granzyme 'B' transcripts during myeloid differentiation of interleukin-3-dependent murine stem cell lines.
- Author
-
Hampson IN, Cross MA, Heyworth CM, Fairbairn L, Spooncer E, Cowling GJ, and Dexter TM
- Subjects
- Amino Acid Sequence, Animals, Base Sequence, Cell Line, Cloning, Molecular, Gene Library, Granulocyte Colony-Stimulating Factor pharmacology, Granulocyte-Macrophage Colony-Stimulating Factor pharmacology, Granzymes, Interleukin-6 pharmacology, Macrophage Colony-Stimulating Factor pharmacology, Mice, Molecular Sequence Data, Open Reading Frames, RNA genetics, RNA isolation & purification, Recombinant Proteins pharmacology, Stem Cells, Transforming Growth Factor beta pharmacology, Cell Differentiation drug effects, Gene Expression Regulation, Enzymologic drug effects, Growth Substances pharmacology, Interleukin-3 pharmacology, Serine Endopeptidases genetics, Transcription, Genetic drug effects
- Abstract
Using the technique of differential cDNA library screening, we have molecularly cloned a gene that is highly expressed in an undifferentiated myeloid multipotent and growth factor-dependent stem cell line (FDCP-Mix) and that downregulates as these cells are induced to differentiate along monocytic, granulocytic, and erythroid cell lineages. Sequence analysis of this gene has shown homology with a previously cloned gene, cytotoxic cell protease 1 (CCP1 or Granzyme 'B'), that has been shown to be expressed only in thymocytes, activated T cells, a mast cell line, and peritoneal exudate leukocytes. In situ hybridization, Northern blot analysis, and nuclear run-off assay has confirmed that expression of CCP1 is restricted to the phenotypically primitive multipotent undifferentiated. FDCP-Mix cells that are undergoing self-renewal in the presence of growth factors such as interleukin-3.
- Published
- 1992